These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

465 related articles for article (PubMed ID: 33705807)

  • 21. Plasma Vascular Endothelial Growth Factor Concentrations after Intravitreous Anti-Vascular Endothelial Growth Factor Therapy for Diabetic Macular Edema.
    Jampol LM; Glassman AR; Liu D; Aiello LP; Bressler NM; Duh EJ; Quaggin S; Wells JA; Wykoff CC;
    Ophthalmology; 2018 Jul; 125(7):1054-1063. PubMed ID: 29525602
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Recent clinically relevant highlights from the Diabetic Retinopathy Clinical Research Network.
    Krick TW; Bressler NM
    Curr Opin Ophthalmol; 2018 May; 29(3):199-205. PubMed ID: 29528861
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Randomized clinical trial evaluating intravitreal ranibizumab or saline for vitreous hemorrhage from proliferative diabetic retinopathy.
    Diabetic Retinopathy Clinical Research Network*
    JAMA Ophthalmol; 2013 Mar; 131(3):283-93. PubMed ID: 23370902
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for diabetic macular oedema.
    Parravano M; Menchini F; Virgili G
    Cochrane Database Syst Rev; 2009 Oct; (4):CD007419. PubMed ID: 19821414
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intravitreal bevacizumab for surgical treatment of severe proliferative diabetic retinopathy.
    di Lauro R; De Ruggiero P; di Lauro R; di Lauro MT; Romano MR
    Graefes Arch Clin Exp Ophthalmol; 2010 Jun; 248(6):785-91. PubMed ID: 20135139
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Vascular Endothelial Growth Factor and Diabetic Retinal Disease.
    Ajlan RS; Silva PS; Sun JK
    Semin Ophthalmol; 2016; 31(1-2):40-8. PubMed ID: 26959128
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Systemic and Ocular Adverse Events with Intravitreal Anti-VEGF Therapy Used in the Treatment of Diabetic Retinopathy: a Review.
    Zehden JA; Mortensen XM; Reddy A; Zhang AY
    Curr Diab Rep; 2022 Oct; 22(10):525-536. PubMed ID: 36053385
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intravitreal bevacizumab for proliferative diabetic retinopathy with new dense vitreous hemorrhage after full panretinal photocoagulation.
    Sinawat S; Rattanapakorn T; Sanguansak T; Yospaiboon Y; Sinawat S
    Eye (Lond); 2013 Dec; 27(12):1391-6. PubMed ID: 24037235
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intraocular pharmacokinetics of anti-vascular endothelial growth factor agents by intraoperative subretinal versus intravitreal injection in silicone oil-filled eyes of proliferative diabetic retinopathy: a randomized controlled pilot study.
    Yao TT; Yang Y; Jin XL; Wang YX; Zhou YL; Xu AJ; He FL; Wang ZY
    Acta Ophthalmol; 2020 Nov; 98(7):e795-e800. PubMed ID: 32114709
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of Aflibercept, Bevacizumab, and Ranibizumab for Treatment of Diabetic Macular Edema: Extrapolation of Data to Clinical Practice.
    Heier JS; Bressler NM; Avery RL; Bakri SJ; Boyer DS; Brown DM; Dugel PU; Freund KB; Glassman AR; Kim JE; Martin DF; Pollack JS; Regillo CD; Rosenfeld PJ; Schachat AP; Wells JA;
    JAMA Ophthalmol; 2016 Jan; 134(1):95-9. PubMed ID: 26512939
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anti-vascular endothelial growth factor for choroidal neovascularisation in people with pathological myopia.
    Zhu Y; Zhang T; Xu G; Peng L
    Cochrane Database Syst Rev; 2016 Dec; 12(12):CD011160. PubMed ID: 27977064
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Correlation between Diabetic Retinopathy Severity and Oxygen Metabolism in Patients with Diabetic Macular Edema during Treatment with Intravitreal Aflibercept.
    Blindbæk SL; Peto T; Grauslund J
    Ophthalmic Res; 2020; 63(2):106-113. PubMed ID: 31715608
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fellow Eye Anti-VEGF 'Crunch' Effect in Retinopathy of Prematurity.
    Wood EH; Rao P; Moysidis SN; Dedania VS; Elman MJ; Drenser KA; Capone A; Trese MT
    Ophthalmic Surg Lasers Imaging Retina; 2018 Sep; 49(9):e102-e104. PubMed ID: 30222828
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for diabetic macular oedema.
    Virgili G; Parravano M; Menchini F; Brunetti M
    Cochrane Database Syst Rev; 2012 Dec; 12():CD007419. PubMed ID: 23235642
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Angiofibrotic response to vascular endothelial growth factor inhibition in diabetic retinal detachment: report no. 1.
    Sohn EH; He S; Kim LA; Salehi-Had H; Javaheri M; Spee C; Dustin L; Hinton DR; Eliott D
    Arch Ophthalmol; 2012 Sep; 130(9):1127-34. PubMed ID: 22965588
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Vitreous mediators after intravitreal bevacizumab or triamcinolone acetonide in eyes with proliferative diabetic retinopathy.
    Arimura N; Otsuka H; Yamakiri K; Sonoda Y; Nakao S; Noda Y; Hashiguchi T; Maruyama I; Sakamoto T
    Ophthalmology; 2009 May; 116(5):921-6. PubMed ID: 19410951
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Vitreous and plasma concentrations of apelin and vascular endothelial growth factor after intravitreal bevacizumab in eyes with proliferative diabetic retinopathy.
    Qian J; Lu Q; Tao Y; Jiang YR
    Retina; 2011 Jan; 31(1):161-8. PubMed ID: 20890241
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anti-vascular endothelial growth factor for neovascular age-related macular degeneration.
    Solomon SD; Lindsley K; Vedula SS; Krzystolik MG; Hawkins BS
    Cochrane Database Syst Rev; 2014 Aug; 8(8):CD005139. PubMed ID: 25170575
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Persistent Macular Thickening Following Intravitreous Aflibercept, Bevacizumab, or Ranibizumab for Central-Involved Diabetic Macular Edema With Vision Impairment: A Secondary Analysis of a Randomized Clinical Trial.
    Bressler NM; Beaulieu WT; Glassman AR; Blinder KJ; Bressler SB; Jampol LM; Melia M; Wells JA;
    JAMA Ophthalmol; 2018 Mar; 136(3):257-269. PubMed ID: 29392288
    [TBL] [Abstract][Full Text] [Related]  

  • 40. APOPTOSIS AND ANGIOFIBROSIS IN DIABETIC TRACTIONAL MEMBRANES AFTER VASCULAR ENDOTHELIAL GROWTH FACTOR INHIBITION: Results of a Prospective Trial. Report No. 2.
    Jiao C; Eliott D; Spee C; He S; Wang K; Mullins RF; Hinton DR; Sohn EH
    Retina; 2019 Feb; 39(2):265-273. PubMed ID: 29190236
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.